BeamMed Now Officially Promotes AEYE Health's Groundbreaking AI Diagnostic Screening Technology

BeamMed has officially partnered with AEYE Health to promote AEYE-DS, an FDA-cleared, AI-based diagnostic screening system that enables rapid, one-minute diabetic retinopathy exams using either handheld or tabletop cameras. Offered through a monthly subscription model, AEYE-DS delivers instant, highly accurate results at the point of care, helping clinics increase screening accessibility, improve patient outcomes, and close care gaps.
Plantation, Florida - BeamMed [https://www.beammed.com/] is proud to announce its official promotion of AEYE Health's state-of-the-art AI diagnostic screening system, AEYE-DS. Developed in Israel, the AEYE solution seamlessly integrates with portable cameras (Optomed Aurora) as well as tabletop cameras to deliver fast, efficient, and highly accurate diabetic retinopathy screenings. This pioneering technology is now available through a flexible monthly subscription model, with a minimum commitment of twelve months. This subscription offers unlimited scans and on-site interpretations that are FDA approved, with an option to include the handheld cameras for clinics that do not already have them.

Revolutionizing Diabetic Retinopathy Screening with Rapid, Accurate AI-Based Exams

AEYE Diagnostic Screening (AEYE-DS) [https://mobilehealthdepot.com/product/aeye-diagnostic-screening/] utilizes advanced artificial intelligence to instantly diagnose diabetic retinopathy from retinal images. It is the only FDA-cleared solution providing autonomous, immediate AI diagnosis using both handheld and tabletop cameras, enabling a one-minute diabetic eye exam at any point of care.

Key Benefits of AEYE Diagnostic Screening

Highly Accurate and Efficient

* 1-Minute Exam: The screening takes only about one minute on average, making it exceptionally fast for point-of-care diagnostics.
* Best-in-Class Performance: Proven to deliver high accuracy with robust sensitivity and specificity in desktop solutions.

Versatile and Practical Application

* Multiple Imaging Options: Compatible with both desktop and portable handheld cameras, the system offers increased flexibility across various clinical settings.
* Simplified Process: Only one image per eye is required, and dilation is rarely necessary, streamlining the exam process and making it accessible for a wide range of healthcare staff.

Immediate Results and Workflow Integration

* Instant Diagnostic Report: The AI system provides immediate diagnostic reports, enabling on-the-spot decision-making and streamlining patient management.
* Point-of-Care Screening: By empowering primary care physicians to perform diabetic retinopathy screenings during routine visits, the technology eliminates delays associated with specialist referrals.

Economic and Care Quality Benefits

* Reimbursable Procedure: With a dedicated CPT code (92229) and alignment with HEDIS/Star quality measures, the screening is not only cost-effective but also instrumental in closing care gaps.
* Closing the Diabetic Eye Exam Gap: With traditional referral-based screening adherence ranging from only 15% to 50%, this autonomous solution offers a practical alternative to ensure timely diagnosis and treatment.

Future Expansion

* Broader Diagnostic Potential: While the current focus is on diabetic retinopathy, the underlying AI platform is being extended to detect other conditions such as glaucoma and age-related macular degeneration, further broadening its impact on eye health.

About BeamMed

BeamMed is committed to advancing healthcare through innovative technology solutions [https://mobilehealthdepot.com/] that enhance clinical workflows and improve patient outcomes. By promoting breakthrough tools like AEYE Health's diagnostic screening system [https://mobilehealthdepot.com/product/aeye-diagnostic-screening/], BeamMed continues to drive the future of accessible, high-quality, and efficient healthcare services.

About AEYE Health

AEYE Health [https://www.aeyehealth.com/] is a digital health company that provides fully autonomous, AI-based diagnostic screening solutions for retinal imaging with best-in-class clinical results and superior usability. The company aims to make diagnostic screening practical, accurate, and accessible. AEYE Health enables point-of-care screening for diabetic retinopathy to ensure that diabetics are regularly screened for diabetic retinopathy. AEYE-DS is the only FDA-cleared autonomous AI for diabetic retinopathy that requires just one image per eye and is the only approved AI for a portable camera.

Media Contact
Company Name: BeamMed Inc.
Contact Person: Gilad Zamir
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=beammed-now-officially-promotes-aeye-healths-groundbreaking-ai-diagnostic-screening-technology]
Phone: 800-769-6808
Address:950 S. Pine Island Road
City: Plantation
State: Florida
Country: United States
Website: http://www.beammed.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.